Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 50 (1), 88-99

18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response

Affiliations
Review

18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response

Simona Ben-Haim et al. J Nucl Med.

Abstract

Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With 18F-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with 18F-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.

Similar articles

See all similar articles

Cited by 97 articles

See all "Cited by" articles

Substances

LinkOut - more resources

Feedback